BrightSpring shares touch three-month high after raising 2026 revenue forecast

By Reuters News

** Home healthcare provider BrightSpring Health's BTSG.O shares hit highest in three months, last up 10% at $66.22

** If levels hold, co is on track to its sharpest one-day percentage gain since May 2025

** Co raises full-year 2026 revenue guidance range again to $15.90 billion-$16.13 billion, from $15.1 billion-$15.43 billion earlier

** Also lifts 2026 adjusted EBITDA forecast to $850 million to $860 million from $820 million-$845 million

** Reports Q3 revenue of $4.21 billion, above analysts' estimate of $3.88 billion, according to data compiled by LSEG

** Quarterly adj. profit of 54 cents per share also surpasses estimate of 47 cents per share

** Co says it saw strong demand for specialty and infusion pharmacy services, higher home healthcare volumes and expansion of acquired branches

** BTSG trades at 27.07 times expected earnings over the next 12 months, compared with 15.77 times for Option Care Health OPCH.O and 16.68 times for Addus HomeCare ADUS.O

** Including session's moves, BTSG up over 78% YTD, outperforming the S&P 400 Health Care Providers & Services .SPMDCHCPS index's 11% gain

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.